Opioid induces increased DNA damage in prefrontal cortex and nucleus accumbens
Pharmacology Biochemistry and Behavior · 2023-03 · 224 · 173535
DOI: 10.1016/j.pbb.2023.173535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2023-03. Verfasst von Yunwanbin Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Heroin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, NIGMS NIH HHS, University of Kansas.
Abstract (Originalsprache)
Opioid use disorder (OUD) is a chronic disease characterized by compulsive opioid taking and seeking, affecting millions of people worldwide. The high relapse rate is one of the biggest challenges in treating opioid addiction. However, the cellular and molecular mechanisms underlying relapse to opioid seeking are still unclear. Recent studies have shown that DNA damage and repair processes are implicated in a broad spectrum of neurodegenerative diseases as well as in substance use disorders. In the present study, we hypothesized that DNA damage is related to relapse to heroin seeking. To test our hypothesis, we aim to examine the overall DNA damage level in prefrontal cortex (PFC) and nucleus accumbens (NAc) after heroin exposure, as well as whether manipulating DNA damage levels can alter heroin seeking. First, we observed increased DNA damage in postmortem PFC and NAc tissues from OUD individuals compared to healthy controls. Next, we found significantly increased levels of DNA damage in the dorsomedial PFC (dmPFC) and NAc from mice that underwent heroin self-administration. Moreover, increased accumulation of DNA damage persisted after prolonged abstinence in mouse dmPFC, but not in NAc. This persistent DNA damage was ameliorated by the treatment of reactive oxygen species (ROS) scavenger N-acetylcysteine, along with attenuated heroin-seeking behavior. Furthermore, intra-PFC infusions of topotecan and etoposide during abstinence, which trigger DNA single-strand breaks and double-strand breaks respectively, potentiated heroin-seeking behavior. These findings provide direct evidence that OUD is associated with the accumulation of DNA damage in the brain (especially in the PFC), which may lead to opioid relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA.
- Department of Pharmacology & Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA; Department of Anesthesiology and Surgical Intensive Care Unit, Xinhua Hospital Affiliated to Shanghai Jiaotong Univer…
- Department of Pharmacology & Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA; Cofrin Logan Center for Addiction Research and Treatment, University of Kansas, Lawrence, KS, USA. Electronic address…
Förderung
- NIDA NIH HHS
- NIGMS NIH HHS
- University of Kansas
- NIH
- National Institute of General Medical Sciences
Zitieren
APA
Wang, Y., Singh, A., Li, G., Yue, S., Hertel, K., & Wang, Z. J. (2023). Opioid induces increased DNA damage in prefrontal cortex and nucleus accumbens. Pharmacology Biochemistry and Behavior, 224, 173535. https://doi.org/10.1016/j.pbb.2023.173535
Vancouver
Wang Y, Singh A, Li G, Yue S, Hertel K, Wang ZJ. Opioid induces increased DNA damage in prefrontal cortex and nucleus accumbens. Pharmacology Biochemistry and Behavior. 2023;224:173535. doi:10.1016/j.pbb.2023.173535
BibTeX
@article{Wang2023,
author = {Wang, Yunwanbin and Singh, Archana and Li, Guohui and Yue, Shuwen and Hertel, Kegan and Wang, Zi-Jun},
title = {Opioid induces increased DNA damage in prefrontal cortex and nucleus accumbens},
journal = {Pharmacology Biochemistry and Behavior},
year = {2023},
volume = {224},
pages = {173535},
doi = {10.1016/j.pbb.2023.173535}
}
EUVIMED